Takeda to sell nonprescription drug unit to Blackstone

Takeda to sell nonprescription drug unit to Blackstone

Photo taken Aug. 24, 2020, in Tokyo shows Alinamin vitamin pills sold by Takeda Consumer Healthcare Co. Takeda Pharmaceutical Co. said the same day it will sell the over-the-counter medicine unit for around 242 billion yen ($2.3 billion) to U.S. investment fund Blackstone Group Inc.

  • Product Code
  • ILEA000200208
  • Registered date
  • 2020/8/24 18:51:33
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2020 Kyodo News
  • Media size
  • 2800 × 3156 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 679.81(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Astrazeneca

    Astrazeneca

    SUQIAN, CHINA - NOVEMBER 20, 2023 - Astrazeneca, Suqian, Jiangsu Province, China, 20 November 2023. (Photo by Costfoto/NurPhoto)
      Astrazeneca

      Astrazeneca

      SUQIAN, CHINA - NOVEMBER 20, 2023 - Astrazeneca, Suqian, Jiangsu Province, China, 20 November 2023. (Photo by Costfoto/NurPhoto)
        Seibu Ikebukuro workers strike

        Seibu Ikebukuro workers strike

        Striking workers represented by a labor union at Japanese department store operator Sogo & Seibu Co. march in the streets of Tokyo's Toshima Ward on Aug. 31, 2023. Store workers are opposing plans by parent Seven & i Holdings Co. to sell the 10-store chain to a U.S.-based investment fund.

          Seibu Ikebukuro workers strike

          TOKYO, Japan - Striking workers represented by a labor union at Japanese department store operator Sogo & Seibu Co. march in the streets of Tokyo's Toshima Ward on Aug. 31, 2023. Store workers are opposing plans by parent Seven & i Holdings Co. to sell the 10-store chain to a U.S.-based investment fund.
            Seibu Ikebukuro workers strike

            Seibu Ikebukuro workers strike

            Photo taken on Aug. 31, 2023, shows the Seibu Ikebukuro department store in Tokyo's Toshima Ward. Store workers staged a strike the same day, opposing plans by parent Seven & i Holdings Co. to sell the 10-store Sogo & Seibu chain to a U.S.-based investment fund.
              Seibu department workers strike

              Seibu department workers strike

              A pedestrian passes by the shuttered flagship Seibu department store in Tokyo's Ikebukuro area on Aug. 31, 2023, amid a labor strike against parent Seven & i Holdings Co.'s planned sale of the 10-store Sogo & Seibu chain to a U.S.-based investment fund.
                Seibu Ikebukuro department store

                Seibu Ikebukuro department store

                Photo taken on Aug. 30, 2023, shows the Seibu Ikebukuro department store in Tokyo. A labor union representing workers at Japanese department stores operated by Sogo & Seibu Co. said the same day that members would go on strike at the store to protest a buyout deal by a U.S.-based investment fund.
                  Seibu Ikebukuro department store

                  Seibu Ikebukuro department store

                  Photo taken on Aug. 30, 2023, shows the Seibu Ikebukuro department store in Tokyo. A labor union representing workers at Japanese department stores operated by Sogo & Seibu Co. said the same day that members would go on strike at the store to protest a buyout deal by a U.S.-based investment fund.
                    U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                    U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                    Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
                      U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                      U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                      Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.